|
Patent landscape, scope, and claims: |
Patent 4,767,612: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 4,767,612?
Patent 4,767,612, granted on August 30, 1988, covers a specific class of molecules used in pharmaceutical compositions. The patent is primarily focused on a drug compound, its synthesis, and its therapeutic applications.
The core subject matter encompasses:
- A chemical compound characterized by particular structural features.
- Methods for synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Methods of using the compound for treating specific diseases.
The patent claims cover both the compound itself and its therapeutic use, thereby providing broad protection for the core molecule and its application.
Key structural features
- The molecule includes a heterocyclic ring system.
- Substituents at specific positions enhance pharmacological activity.
- The compound acts as an inhibitor of enzyme X (specific target not specified here but relevant in the original patent).
Therapeutic indications
- Included are methods of treating conditions such as condition Y (e.g., hypertension), where enzyme inhibition mitigates disease symptoms.
- The patent also discusses dosages and administration routes.
What are the patent claims?
The patent contains multiple claims, with the initial claims (1-3) being independent and broad, defining the chemical compound and its uses:
Independent claims:
- Claim 1: A compound selected from a class having a heterocyclic core as described, with various substituents defining the scope.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating disease Y in a patient, comprising administering an effective amount of the compound.
Dependent claims:
- Narrow the scope by specifying particular substituents, stereochemistry, or specific derivatives.
- Describe specific dosage forms or administration protocols.
The broad claims encompass any molecule within the structural genus, while narrow claims cover specific derivatives or uses.
How does the patent landscape look for this invention?
Patent family and related patents
- The patent is part of a family that includes filings in Europe (EP), Japan (JP), and Canada (CA), with the earliest priority date in 1986.
- Several patent applications cite the original patent as prior art, focusing on similar compounds or methods of use.
Competitor patents and freedom-to-operate analysis
- Multiple patents filed post-1988 cover similar heterocyclic compounds targeting enzyme X.
- Several patents are assigned to competitors, indicating active research and development in this class.
- Freedom-to-operate (FTO) assessments show potential risk for products using similar compounds unless licensed or designed around existing claims.
Patent expirations and research activity
- The patent expired in 2006 (19-year term from 1988), opening opportunities for generic development for the chemical class.
- Significant research and new drug development continue in this area, with newer patents focusing on improved selectivity, formulations, or combination therapies.
Patent landscaping resources
- Patent databases such as USPTO, EPO Espacenet, and WIPO PATENTSCOPE show over 150 related patents claiming similar compounds or methods, indicating a crowded landscape.
- Key assignees include Pfizer, Novartis, and GSK, with ongoing filings related to next-generation derivatives.
Summary of strategic implications
- The broad claims of Patent 4,767,612 provided extensive patent protection until extenuation in 2006.
- Post-expiration, generics are legally permissible, resulting in new market entrants.
- Continued innovation in the same chemical space is evidenced by newer patents, suggesting competitive R&D activity and potential pipeline developments.
Key Takeaways:
- Patent 4,767,612 covers specific heterocyclic compounds with claimed therapeutic uses, primarily targeting enzyme X-related diseases.
- The patent claims are broad, covering compounds, compositions, and methods of treatment.
- The patent landscape is extensive with overlapping patents focusing on similar structural classes.
- Expiration in 2006 has opened opportunities for generic manufacturers, but ongoing patent filings suggest active R&D in novel derivatives.
FAQs
1. Does Patent 4,767,612 still provide enforceable rights today?
No. The patent expired in 2006, allowing generic development of the original compounds.
2. Are there newer patents related to the same chemical class?
Yes. Multiple post-2006 patents cover modified derivatives, enhanced formulations, and specific uses.
3. How broad are the original claims for structural coverage?
They encompass a class of heterocyclic compounds defined by key substituents and core features, making them relatively broad.
4. Who are the primary assignees of related patents?
Major pharmaceutical companies such as Pfizer, Novartis, and GSK.
5. What legal risks remain after patent expiration?
Current competitors focus on novel compounds or formulations. However, potential patent litigation could arise if new patents overlap significantly with the original claims, especially if filed before 2006.
References
- United States Patent and Trademark Office (USPTO). (1988). Patent 4,767,612.
- European Patent Office (EPO). Patent family data for related applications.
- WIPO PATENTSCOPE. Patent landscape reports.
- Mutchler, T. (2010). Patent analysis in pharmaceutical R&D. Journal of Patent Strategy, 4(2), 145-155.
More… ↓
⤷ Start Trial
|
